Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (November 2024)
24 slides from Arbutus Biopharma's investor presentation, Nov 6, 2024
Slide 1: Corporate Presentation
NASDAQ: ABUS www.arbutusbio.com November 6, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: Arbutus Biopharma (ABUS) Overview
Arbutus Biopharma (ABUS) Overview ~250M 1 people have cHBV with current treatment options for most patients limited to life - long suppressive therapy, representing a need for a finite curative regimen. HBV Represents a Large Commercial Opportunity ` Phase 2a clinical trial data with imdusiran shows
Slide 4: Strategy for Value Creation
PHASE 1 PHASE 2 PHASE 3 Strategy for Value Creation Develop a combination therapy that includes antivirals and immunomodulators to provide a finite, curative treatment for people with chronic HBV Imdusiran (AB - 729) RNAi Therapeutic (Subcutaneous) AB - 101 PD - L1 Inhibitor (Oral) cHBV Program AB -
Slide 5: HBV: A Global Public Health Threat with a Significant Unmet Medical Need
Chronic HBV (2M in U.S.) >250M HBV: A Global Public Health Threat with a Significant Unmet Medical Need Treated 7M 3% Diagnosed 32M 13% Sources: https://www.who.int/news - room/fact - sheets/detail/hepatitis - b https://www.hepb.org/what - is - hepatitis - b/what - is - hepb/facts - and - figures/ P
Slide 6: Rationale for a Functional Cure in HBV
6 © 2024 Arbutus Biopharma, Inc. Rationale for a Functional Cure in HBV Prevent complications of disease progression - HBsAg loss is strongly associated with a reduced risk of long - term adverse clinical outcomes observed among cHBV patients regardless of the presence of cirrhosis. 2, 3 Decrease HB
Slide 7: 3-Pronged Approach to Therapeutic Success
Suppress Reduce Boost Viral DNA Viral Antigen - HBsAg Host Immune System Leading to an HBV Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune response 7 NA RNAi RN
Slide 8: Imdusiran RNAi Therapeutic
8 © 2024 Arbutus Biopharma, Inc. Imdusiran RNAi Therapeutic
Slide 9: Imdusiran GalNAc-conjugate delivery technology
Proprietary GalNAc - conjugate delivery technology provides liver targeting and enables subcutaneous dosing Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activity across HBV genotypes Demonstrated complementarity with oth
Slide 10: Imdusiran: Key Takeaways from Clinical Trials to Date
Imdusiran: Key Takeaways from Clinical Trials to Date Imdusiran provided robust and comparable HBsAg declines (~1.5 - 2.0 log 10 ) regardless of dose, dosing interval, HBeAg or DNA status When combined with a NA and a short course of IFN, imdusiran led to HBsAg loss in up to 67% of patients with HBs
Slide 11: Phase 2a POC Clinical Trial: IM-PROVE I
Phase 2a POC Clinical Trial Imdusiran in combination with ongoing NA therapy and short courses of Peg - IFN α - 2 a in cHBV patients IM - PROVE I: POC: Proof of Concept Primary objective : evaluate safety and tolerability of imdusiran in combination with Peg - IFN α - 2a in patients with NA - suppre
Slide 12: IM-PROVE I: Imdusiran with Short Courses of IFN Leads to Sustained HBsAg Loss
IM - PROVE I: Imdusiran with Short Courses of IFN Leads to Sustained HBsAg Loss Cohort A2: IDR x 4 + NA + IFN x 24W (N = 13) Cohort A1: IDR x 6 + NA + IFN x 24W (N = 12) Achieved HBsAg ≤ LLOQ (0.05 IU/mL) 3/13 (23%) 4/12 (33.3%) EOT (W52) 7/25 (28%) 2/13 (15.4%) 4/12 (33.3%) 24 weeks post - EOT (NA
Slide 13: IM-PROVE I: Sustained HBsAg Loss in 6 Patients
IM - PROVE I: Imdusiran with 24 Weeks of IFN Leads to Sustained HBsAg Loss in 6 patients Data presented at EASL 2024 13 © 2024 Arbutus Biopharma, Inc.
Slide 14: Phase 2a POC Clinical Trial: IM-PROVE II
Phase 2a POC Clinical Trial Evaluating imdusiran in combination with Barinthus Bio’s immunotherapeutic, VTP - 300, and NA with or without low dose nivolumab IM - PROVE II: Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP - 300 or placebo At Week 48 all participants
Slide 15: IM-PROVE II: Imdusiran and VTP-300 Lower HBsAg Levels
IM - PROVE II: Imdusiran and VTP - 300 Achieve Statistical Significance in Lowering HBsAg Levels 15 © 2024 Arbutus Biopharma, Inc. Imdusiran led to declines of - 1.8 log10 by Week 26, 95% of subjects had HBsAg <100 at time of VTP - 300 or placebo dosing More subjects maintained HBsAg thresholds of <
Slide 16: Strategic Collaboration and Exclusive Licensing with Qilu
Strategic Collaboration Exclusive Licensing* and Strategic Partnership Develop, manufacture and commercialize imdusiran in mainland China, Hong Kong, Macau and Taiwan Imdusiran Upfront payment (received in 2022) $40M Equity investment (received in 2022) $15M Commercialization and milestone payments
Slide 17: AB-101 Oral PD-L1 Checkpoint Inhibitor
17 © 2024 Arbutus Biopharma, Inc. AB - 101 Oral PD - L1 Checkpoint Inhibitor
Slide 18: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation
AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation PD - 1: Programmed death ligand protein | Abs: Antibodies Currently in a Phase 1a/1b clinical trial Rationale • HBV immune tolerance is a critical driver of cHBV infection • PD - 1:PD - L1 checkpoint axis plays a key role in immune toleriz
Slide 19: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV
AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV AB - 101 is highly potent and activates HBV specific immune cells from chronic HBV patients AB - 101 reinvigorates HBV - specific cHBV patient T - cells PBMCs N= cells from 9 cHBV patients *p< - 0.05 PBMC: P eripheral Blood Mononuclear Cells
Slide 20: AB-101-001: Phase 1a/1b Clinical Trial
20 © 2024 Arbutus Biopharma, Inc. Part 1: SAD (n=8/cohort – 6:2) 1C: 10 mg 1B: 3 mg 1A: 1 mg Part 2: MAD (n=10/cohort – 8:2) 2A: 10 mg daily x 7 days 2B: 25 mg daily x 7 days † 3A: 10 mg daily x 28d 3B: Dose/interval TBD x 28d 3C: Dose/interval TBD x 28d AB - 101 - 001: Phase 1a/1b Clinical Trial wi
Slide 21: LNP Litigation: Update
LNP Litigation: Update Moderna - Trial date September 24, 2025 (subject to the Court’s availability)* • Markman Hearing occurred February 8, 2024 – judge heard arguments on claim construction – Court provided ruling on April 3 and agreed with Arbutus’s position on the majority of the claims • Next S
Slide 22: 2024 Key Milestones
2024 Key Milestones 22 Anticipated Timing 2024 Milestone 1H IM - PROVE I Phase 2a ( imdusiran + IFN): End - of - treatment data 1H IM - PROVE II Phase 2a ( imdusiran + VTP - 300): End - of - treatment data 1H AB - 101 - 001: Preliminary data from healthy subject cohorts 2H IM - PROVE II Phase 2a ( i
Slide 23: Investment Highlights
Investment Highlights Strong financial position Indication with significant unmet medical need & large market opportunities Patented LNP technology Portfolio of internally discovered assets with distinct MOAs Lead HBV compound – imdusiran (AB - 729) RNAi therapeutic in multiple Phase 2a combination
Slide 24: Thank You
Thank You 24 © 2024 Arbutus Biopharma, Inc.
Arbutus Biopharma — Investor Presentation (November 2024) on 6ix